Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies

References

• Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer. 2017;64:10. doi:10.1002/pbc.26542
   Web of Science ®Google Scholar
• Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017;25(1):303–308. doi:10.1007/s00520-016-3449-y27815710
   PubMed Web of Science ®Google Scholar
• Frame DG. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol. 2010;8(2 Suppl 1):5–9.20629452
   PubMedGoogle Scholar
• Dupuis LL, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57(2):191–198. doi:10.1002/pbc.2311421465637
   PubMed Web of Science ®Google Scholar
• Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60(7):1073–1082. doi:10.1002/pbc.2450823512831
   PubMed Web of Science ®Google Scholar
• Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl_5):v119–v133. doi:10.1093/annonc/mdw27027664248
   PubMed Web of Science ®Google Scholar
• Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther. 2010;17(5):476–486. doi:10.1097/MJT.0b013e3181ea782120844345
   PubMed Web of Science ®Google Scholar
• Phillips RS, Friend AJ, Gibson F, et al. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Sys Rev. 2016;2:Cd007786. doi:10.1002/14651858.CD004158.pub3
   PubMed Web of Science ®Google Scholar
• Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003;25(5):1407–1419.12867217
   PubMed Web of Science ®Google Scholar
• Celio L, Ricchini F, De Braud F. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence. 2013;7:391–400. doi:10.2147/PPA.S3128823687442
   PubMed Web of Science ®Google Scholar
• Saito Y, Kumamoto T, Arima T, et al. Evaluation of aprepitant and fosaprepitant in pediatric patients. Pediatr Int. 2019. doi:10.1111/ped.13780.
   Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090–3098. doi:10.1002/cncr.1143312784346
   PubMed Web of Science ®Google Scholar
• Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20(4):450–458. doi:10.1634/theoncologist.2014-022925795636
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. EMEND - Fosaprepitant Dimeglumine. NDA 022023 - SUPPL-17. SUPPL-17 2018; FDA Approval. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM605696.pdf. Accessed 1212, 2018
   Google Scholar
• Okumura LM, D’Athayde Rodrigues F, Ferreira MAP, Moreira LB. Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials. Br J Clin Pharmacol. 2017;83(5):1108–1117. doi:10.1111/bcp.1319327868231
   PubMed Web of Science ®Google Scholar
• Radhakrishnan V, Joshi A, Ramamoorthy J, et al. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer. 2018;e27551.30426714
   PubMed Web of Science ®Google Scholar
• Timaeus S, Elder J, Franco K. Evaluation of the use of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. J Pediatr Hematol Oncol. 2018;40(7):527–531. doi:10.1097/MPH.000000000000121329794645
   PubMed Web of Science ®Google Scholar
• European Parliament and Council. Directive 2001/20/EC of the European Parliament and of the Councol of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medical Products for Human Use. In. Vol 2001/20/EC2001. European Parliament; 2001:34–44.
   Google Scholar
• European Medicines Agency (EMA) - Committee for Medicinal Products for Human Use (CHMP). Assessment report Ivemend - Procedure No. EMEA/H/C/000743/II/0037. 2018; https://www.ema.europa.eu/documents/variation-report/ivemend-h-c-743-ii-0037-epar-assessment-report-variation_en.pdf. Accessed 1212, 2018
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines - Antiemesis. Version 2.2017. National Comprehensive Cancer Network; 2017.
   Google Scholar
• U.S. NIH -NCI. Common Terminology Criteria for Adverse Events v4.03 (CTCAE) 2010. May 28, 2009, 2010.
   Google Scholar
• Ethier MC, Regier DA, Tomlinson D, et al. Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer. Support Care Cancer. 2012;20(8):1771–1777. doi:10.1007/s00520-011-1274-x21947490
   PubMed Web of Science ®Google Scholar
• Wong HM. Oral complications and management strategies for patients undergoing cancer therapy. TheScientificWorldJournal. 2014;2014:581795. doi:10.1155/2014/581795
   PubMed Web of Science ®Google Scholar
• Cheng KK, Goggins WB, Lee VW, Thompson DR. Risk factors for oral mucositis in children undergoing chemotherapy: a matched case-control study. Oral Oncol. 2008;44(11):1019–1025. doi:10.1016/j.oraloncology.2008.01.00318329325
   PubMed Web of Science ®Google Scholar
• Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104(4):864–868. doi:10.1002/cncr.2122215973669
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the aprepitant protocol 052 study group. J Clin Oncol. 2003;21(22):4112–4119. doi:10.1200/JCO.2003.01.09514559886
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423–431. doi:10.1007/s00520-009-0680-919568773
   PubMed Web of Science ®Google Scholar
• Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24(4):1067–1073. doi:10.1093/annonc/mds54123117073
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822–2830. doi:10.1200/JCO.2005.09.05015837996
   PubMed Web of Science ®Google Scholar
• Shillingburg A, Biondo L. Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther. 2014;19(2):127–131. doi:10.5863/1551-6776-19.2.12725024673
   PubMedGoogle Scholar
• Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010;21(12):2316–2323. doi:10.1093/annonc/mdq14920488873
   PubMed Web of Science ®Google Scholar
• Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017. doi:10.1111/bcp.13322
   Web of Science ®Google Scholar
• Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced encephalopathy precipitated by aprepitant: a rarely manifested side effect of drug interaction. J Pharmacol Pharmacother. 2017;8(1):38–40. doi:10.4103/jpp.JPP_182_1628405136
   PubMed Web of Science ®Google Scholar
• Dushenkov A, Kalabalik J, Carbone A, Jungsuwadee P. Drug interactions with aprepitant or fosaprepitant: review of literature and implications for clinical practice. J Oncol Pharm Pract. 2017;23(4):296–308. doi:10.1177/107815521663140826921085
   PubMed Web of Science ®Google Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29(11):1495–1501. doi:10.1200/JCO.2010.31.785921383291
   PubMed Web of Science ®Google Scholar